Group 1 - Morgan Stanley increased its stake in Innovent Biologics (01801) by 1,233,667 shares at a price of HKD 78.6975 per share, totaling approximately HKD 97.0865 million [1] - Following the increase, Morgan Stanley's total shareholding in Innovent Biologics reached approximately 87,914,900 shares, representing a stake of 5.06% [1]

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by acquiring 1.2337 million shares at an average price of HKD 78.6975 per share, totaling approximately HKD 97.0865 million [1] - Following this acquisition, JPMorgan's total holdings in Innovent Biologics rose to 87.9149 million shares, increasing its ownership percentage from 4.99% to 5.06% [1]

Core Viewpoint - Goldman Sachs has raised the earnings per share (EPS) forecasts for Innovent Biologics (01801) for 2025 to 2027, reflecting a positive outlook on the company's financial performance despite some challenges in the market [1] Financial Performance - The product revenue for Innovent Biologics in the fourth quarter of last year was approximately 3.3 billion RMB, meeting Goldman Sachs' expectations, with a year-on-year growth of 60% from a relatively low base, remaining flat quarter-on-quarter [1] - The company's new product portfolio continues to show growth, with a quarterly increase of 13%, which offsets the weak performance of Tyvyt [1] - For the full year of 2025, product sales are expected to be strong, with a projected year-on-year growth of 45% to 11.9 billion RMB, marking the first time sales exceed the 10 billion RMB milestone, driven primarily by the growth in the biopharmaceutical business [1] Target Price and Rating - The target price for Innovent Biologics has been adjusted to 102.85 HKD from the previous 107.96 HKD, while maintaining a "Buy" rating [1]

Core Viewpoint - Goldman Sachs has raised the earnings per share forecast for Innovent Biologics (01801) for 2025 to 2027, with target prices adjusted to HKD 102.85 from HKD 107.96, maintaining a "Buy" rating [1] Group 1: Earnings Forecast - The earnings per share estimates for Innovent Biologics have been increased to HKD 0.62, HKD 1.74, and HKD 2.54 for the years 2025, 2026, and 2027 respectively, up from HKD 0.54, HKD 1.43, and HKD 2.49 [1] - The company is expected to achieve a strong product sales performance in 2025, with a projected year-on-year growth of 45% to reach RMB 11.9 billion, marking a significant milestone of surpassing RMB 10 billion [1] Group 2: Revenue Performance - In the fourth quarter of the previous year, the product revenue was approximately RMB 3.3 billion, aligning with Goldman Sachs' expectations, and reflecting a year-on-year growth of 60% from a relatively low base, while remaining flat quarter-on-quarter [1] - The new product portfolio continues to show growth momentum, with a quarterly increase of 13%, which offsets the weak performance of Tyvyt [1]

Core Viewpoint - In 2025, Innovent Biologics (01801.HK) reported strong product revenue growth for Q4 and the entire year, yet its stock price declined by 0.93% to HKD 79.90, with a market capitalization of HKD 138.6 billion [2] Group 1: Financial Performance - The company expects total product revenue for 2025 to reach approximately RMB 11.9 billion, reflecting a year-on-year growth of about 45%, compared to a 43.64% increase in 2024 and a 37.32% increase in the first half of 2025, indicating accelerated growth in the second half of the year [3] - In Q4 2025, total product revenue is projected to exceed RMB 3.3 billion, representing over 60% year-on-year growth, significantly higher than the first three quarters [3] - For the first half of 2025, revenue increased by 50.62% to RMB 5.953 billion, with pharmaceutical product sales rising by 37.32% to RMB 5.234 billion, and non-GAAP EBITDA turning profitable at RMB 1.413 billion [7] Group 2: Product Pipeline and Approvals - Innovent's commercial product portfolio has expanded to 18 products, with the recent approvals of new drugs such as Daberhe (Ipilimumab N01 injection) and Xinmeiyue (Pikankizumab injection) [3][4] - Daberhe is noted as the first domestically approved anti-CTLA-4 monoclonal antibody in China, enhancing the treatment landscape for colon cancer [3] - The company has seven innovative products included in the new national medical insurance directory, which may boost sales but could also pressure revenue growth due to lower pricing [8] Group 3: Market Position and Future Outlook - Innovent has successfully transitioned from a startup biotech firm to a profitable and influential innovative pharmaceutical company, with a diverse treatment portfolio covering oncology, autoimmune diseases, cardiovascular, and metabolic disorders [9] - Despite the positive fundamentals, the market remains cautious about short-term profitability due to pricing pressures from new drug inclusions in the insurance directory [9] - Future growth is anticipated with multiple new indications and innovative drugs awaiting approval, suggesting strong growth momentum if the company can balance insurance volume with profit structure [9]

本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 11 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 信達生物製藥 | | | | | | 呈交日期: | 2026年2月5日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 01801 | 說明 | 普通股 | | | 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 5,000,000,000 USD 0.00001 USD 50,000 增加 / 減少 (-) 0 USD 0 本月底結存 5,000,000,000 USD 0.00001 USD 50,000 II. 已發行股份及/或庫存 ...

Core Viewpoint - The company, Innovent Biologics, announced that it expects total product revenue to reach approximately 11.9 billion RMB in 2025, representing a year-on-year growth of about 45% [1] Group 1: Revenue Growth - In the fourth quarter of 2025, the company anticipates total product revenue of around 3.3 billion RMB, reflecting a year-on-year increase of over 60% [1] - The revenue growth is attributed to the inclusion of six new drugs in the 2026 National Medical Insurance Directory, leading to a one-time inventory adjustment [1] Group 2: Product Portfolio and Market Position - The company continues to solidify its leading position in the oncology treatment sector, expanding its oncology product portfolio to 13 products, with increasing synergy effects [1] - Core products, such as Tyvyt® (sintilimab injection), are maintaining steady growth, while several new products are significantly contributing to revenue increases [1] Group 3: Chronic Disease Commercialization - The company has successfully expanded into the chronic disease commercialization field, achieving notable results [1] - Products like Xinlima® (mashutide injection), Xinbile® (toripalimab injection), and Xinbimin® (tremelimumab N01 injection) are experiencing accelerated market growth and have become key drivers of revenue growth [1]

每经AI快讯，信达生物(01801.HK)现跌近4%，截至发稿，跌3.72%，报77.65港元，成交额5.19亿港元。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the article highlights that Innovent Biologics (01801) has achieved significant revenue growth, with total product revenue reaching approximately RMB 11.9 billion in 2025, marking a 45% year-on-year increase and surpassing the RMB 10 billion milestone for the first time [1] - In Q4 2025, the company reported total product revenue of approximately RMB 3.3 billion, reflecting over 60% year-on-year growth, indicating a strong growth momentum [1] - The announcement notes that in Q4 2025, due to six new drugs being included in the 2026 National Medical Insurance Directory, Innovent Biologics accounted for a one-time inventory adjustment based on original pricing for products distributed to channels [1] Group 2 - Haitong International expressed that despite the one-time inventory adjustment impact, the company's Q4 performance met their expectations, and they remain optimistic about the accelerated market penetration of the six new drugs following their inclusion in the insurance directory [1]

Core Viewpoint - The company achieved a total product revenue of approximately RMB 11.9 billion in 2025, marking a 45% year-on-year increase and surpassing the RMB 10 billion milestone for the first time [1] Group 1: Financial Performance - In the fourth quarter of 2025, the company reported total product revenue of approximately RMB 3.3 billion, reflecting a year-on-year growth of over 60% [1] - The strong growth momentum is expected to continue, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 2: Market Impact - The company accounted for a one-time inventory adjustment due to the distribution of products at original prices, following the inclusion of new drugs in the insurance directory [1] - Haitong International expressed that the fourth-quarter performance met their expectations, and they are optimistic about the accelerated market penetration of the six new drugs post-inclusion in the insurance directory [1]